Embryo Transfer, In Vitro Fertilization (IVF)
Conditions
Brief summary
Impact of dual trigger using recombinant human chorionic gonadotropin (HCG) and gonadotropin-releasing hormone (GnRH) agonist on thawed modified natural cycle outcomes: an open-label multi-center randomized controlled trial.
Interventions
DRUGGnRH agonist
GnRH agonist add to hcg for trigger
Sponsors
National Taiwan University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
25 Years to 44 Years
Healthy volunteers
Yes
Inclusion criteria
1\. 24\<= Age \< 45 patient undergo mNC-FET
Exclusion criteria
1\. Congenital or acquired uterine abnormalities (uterine malformation, submucosal myoma, intrauterine adhesion or endometrial polyp \>1cm)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Implantation | 14 days after embryo transfer | Implantation is defined as a positive serum β-hCG (\>20 mIU/mL) measured 14 days after embryo transfer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ongoing pregnancy rate | 5 weeks after confirmed pregnancy | An ongoing pregnancy is defined as a viable intrauterine pregnancy with fetal cardiac activity at ≥9 weeks' gestational age. |
| Miscarriage rate | before delivery | — |
| Gestational age (weeks) at delivery | delivery | Gestational age (weeks) at delivery |
| Clinical pregnancy | one week after confirm pregnancy | Clinical pregnancy is defined as visualization of a gestational sac on transvaginal ultrasonography one week after pregnancy has been confirmed. |
| Birth weight | delivery | Birth weight of the bewborn (kg) |
| Presence of significant congenital or medical conditions of the newborn | delivery | Presence of significant congenital or medical conditions of the newborn |
| Live birth rate | delivery | — |
Contacts
Primary Contactwilliam lee
Outcome results
None listed